Long-Term Effects of Hormone Therapy on Women’s Health: A Review

Long-term use of menopausal hormone therapy for at least one year yields distinct health profiles depending on whether patients take combined oestrogen-progestogen regimens or oestrogen alone. Clinical reviews indicate that while combined continuous therapy reduces bone fractures, it increases breast cancer and stroke risks, whereas oestrogen-only therapy presents different outcomes.

Navigating the transition through perimenopause and postmenopause has required balancing immediate symptom relief against long-term physiological outcomes. Recent evidence syntheses have sharpened our understanding of how these pharmaceutical interventions alter baseline physiological risks over extended periods. Because formulations, doses, and delivery methods have evolved considerably since foundational clinical trials were launched in the 1990s, contemporary clinical evaluation demands a granular look at the data.

In Plain English: The Clinical Takeaway

• Different Regimens, Different Profiles: Taking oestrogen alone versus combining it with progestogen changes the spectrum of long-term health outcomes, particularly regarding uterine and breast tissues.
• Fracture Risk Reduction: Both combined continuous therapy and oestrogen-only treatments reliably decrease the incidence of bone fractures over time.
• Cardiovascular and Oncological Trade-offs: Long-term use introduces measurable statistical increases in specific conditions, such as strokes, venous blood clots, and breast cancer, requiring individualized risk-benefit assessments.

Physiological Mechanisms and Clinical Trial Findings

Menopause occurs naturally when the ovaries cease releasing eggs and reduce hormone production, diagnosed clinically after 12 consecutive months without a menstrual period. This transitional drop in hormone levels impacts the heart, blood vessels, and bones, elevating risks for osteoporosis, high blood pressure, and heart disease. Hormone therapy (HT) utilizes exogenous hormones to mitigate vasomotor symptoms like hot flushes and night sweats.

According to comprehensive data evaluations examining randomized controlled trials against inactive placebos, the physiological impacts diverge based on the pharmacological structure. For women with a womb (uterus), combined hormone therapy (oestrogen paired with progestogen) is used to protect against cancer of the womb lining (endometrial cancer). Conversely, women who have undergone a hysterectomy can utilize oestrogen-only therapy.

Evidence drawn from major randomized trials involving thousands of participants reveals specific statistical shifts over multi-year follow-up periods. For combined continuous hormone therapy evaluated at roughly 5.5 years, data demonstrates a reduced risk of bone fractures—dropping from approximately 111 down to 87 per 1,000 women. However, this benefit is weighed against an increase in breast cancer (rising from 19 to 24 per 1,000 women). Furthermore, combined therapy may increase the incidence of stroke, blood clots in a vein, and gallbladder disease requiring surgical intervention.

For oestrogen-only therapy evaluated at seven years of follow-up in post-hysterectomy cohorts, the data shows distinct variances. While bone fractures similarly decreased from 141 to 103 per 1,000 women, oestrogen-alone regimens showed little to no difference regarding heart attacks, blood clots in a vein, or breast cancer incidence. Yet, oestrogen-only therapy increased the statistical probability of stroke and gallbladder disease.

Comparative Health Outcomes of Long-Term Hormone Therapy vs. Placebo

Clinical Outcome	Combined Continuous HT (per 1,000)	Oestrogen-Only HT (per 1,000)
Bone Fractures	Reduced (111 to 87)	Reduced (141 to 103)
Breast Cancer	Increased (19 to 24)	Little or no difference
Stroke	Increased (13 to 18)	Increased (24 to 32)
Blood Clot in a Vein	Increased (10 to 20)	Little or no difference
Gallbladder Disease	Increased (16 to 27)	Increased (27 to 47)

Methodological Limitations and Regulatory Context

Evaluating these clinical outcomes requires careful consideration of historical trial designs. The foundational data driving these metrics largely originated from large-scale trials conducted during the 1990s. These studies predominantly administered hormone therapy as tablets taken by mouth. Contemporary clinical practice, however, incorporates different ways to take it, different hormone types, and updated doses.

Additionally, approximately 30 percent of participants in these foundational studies were aged 50 to 59 at baseline, leaving a knowledge gap regarding women under 50 years or women whose ovaries have stopped working because of medical treatment.

Conclusion

The long-term effects of menopausal hormone therapy represent a complex interplay of systemic benefits and targeted physiological risks. While bone health is consistently protected across regimens, cardiovascular and oncological considerations require personalized clinical oversight. As research methods and delivery systems continue to evolve, ongoing dialogue between patients and healthcare providers remains the cornerstone of safe, effective menopausal management.

References

• Cochrane Database of Systematic Reviews – Long-term hormone therapy for perimenopausal and postmenopausal women.